Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Stockholders Deficit (Details Textual)

v3.24.0.1
Note 7 - Stockholders Deficit (Details Textual) - USD ($)
3 Months Ended
Nov. 30, 2023
Oct. 01, 2022
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)     0    
Non Employee Restricted Shares [Member]          
Share-Based Payment Arrangement, Expense     $ 0 $ 2,000  
Research and Development Expense [Member]          
Share-Based Payment Arrangement, Expense     6,000 14,000  
General and Administrative Expense [Member]          
Share-Based Payment Arrangement, Expense     23,000 90,000  
Employees Directors And Consultants [Member]          
Share-Based Payment Arrangement, Expense     29,000 104,000  
The 2013 Plan [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized   185,571     170,571
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized   15,000      
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount     $ 85,000    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition     1 year 1 month 2 days    
Conversion of Series 2 Convertible Notes and Interest Into Common Stock [Member]          
Debt Conversion, Converted Instrument, Shares Issued 52,918        
Debt Conversion, Converted Instrument, Amount $ 450,000   $ 587,959 $ 0  
Debt Conversion, Original Debt, Amount, Interest $ 137,946